STRENGTH Trial

Study / Research

Another large trial of high-dose omega-3s (predominantly EPA with DHA) that, when compared to a corn oil placebo, showed essentially no cardiovascular benefit, contrasting with REDUCE-IT.

Mentioned in 3 videos

Videos Mentioning STRENGTH Trial

#134 - James O’Keefe, M.D.: Preventing cardiovascular disease and the risk of too much exercise

#134 - James O’Keefe, M.D.: Preventing cardiovascular disease and the risk of too much exercise

Peter Attia MD

A trial that investigated combined EPA and DHA, but was halted early, leaving questions about the optimal form of omega-3.

#147-Hussein Yassine, M.D.: Deep dive into the “Alzheimer’s gene” (APOE), brain health, and omega-3s

#147-Hussein Yassine, M.D.: Deep dive into the “Alzheimer’s gene” (APOE), brain health, and omega-3s

Peter Attia MD

Another large trial of high-dose omega-3s (predominantly EPA with DHA) that, when compared to a corn oil placebo, showed essentially no cardiovascular benefit, contrasting with REDUCE-IT.

#83 – Bill Harris, Ph.D.: Omega-3 fatty acids

#83 – Bill Harris, Ph.D.: Omega-3 fatty acids

Peter Attia MD

A large ongoing clinical trial (13,000 patients) testing 4 grams total of EPA plus DHA (Epanova, as free fatty acids) with similar inclusion criteria to REDUCE-IT, expected to finish in about a year and be released at American Heart in 2020.